These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26099278)

  • 1. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
    J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
    Hapani S; Chu D; Wu S
    Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.
    Qi WX; Shen F; Qing Z; Xiao-Mao G
    Tumour Biol; 2014 Nov; 35(11):10715-22. PubMed ID: 25070487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
    Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
    JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
    Qi WX; Shen Z; Tang LN; Yao Y
    Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
    Xiao B; Wang W; Zhang D
    Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
    Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
    Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Sashegyi A; Zhang Y; Lin Y; Binder P; Ferry D
    J Chemother; 2017 Feb; 29(1):62-64. PubMed ID: 27077927
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
    Hapani S; Sher A; Chu D; Wu S
    Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HC
    J Glob Oncol; 2018 Jul; 4():1-12. PubMed ID: 30085888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.